STEVENSON, Md., Oct. 1, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California in addition to the action filed in the United States District Court for the District of New Jersey on behalf of purchasers of Impax Laboratories Inc. ("Impax" or the "Company") (Nasdaq: IPXL ) securities during the period between May 20, 2013 and July 28, 2014, inclusive (the "Class Period").
If you have suffered a loss from investment in Impax securities purchased on or after May 20, 2013 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html . You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than October 13, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that its failure to adhere to proper quality control and manufacturing practices at its Taiwan production facility could adversely effect its ability to launch its new drug, RYTARY and that the quality control and manufacturing issues were imperiling its ability to produce, sell, and distribute generic drugs. According to the complaint, following the Company's July 29, 2014 announcement that the FDA had completed an inspection of the Company's Taiwan facility that revealed deficiencies, the value of Impax shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616
